Harry joined Bristows as a trainee solicitor in August 2020 and qualified in 2022. He now advises primarily on non-contentious IP and technology matters across a wide range of sectors including pharmaceuticals, biotech and other industrial fields.

Harry has a background in chemistry (including a master’s in inorganic catalysis). He specialises in life science transactions involving the development, transfer and/or exploitation of IP rights. He has recently been on secondment to a leading global pharmaceutical company where he advised on life science transactions including a high-value license and supply agreement involving controlled drugs. While seconded, Harry worked closely with their in-house legal, commercial, and brands teams.

He has also previously completed a secondment with the in-house legal team of a major international technology company.